BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BioCentury  |  Product Development

Dissipating a Slow Torture

Addex reports impact on uncontrolled movement in Parkinson's dyskinesia

While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea and dystonia components of the condition. The company now hopes to replicate that effect in a Phase II trial of lead compound ADX48621 due to start this quarter.

Levodopa is used to treat the signs and symptoms of PD, but long-term use frequently results in involuntary movement known as levodopa-induced dyskinesia (LID). Dyskinesia has two main components: chorea (sudden, rapid uncontrolled movements) and dystonia (slow, writhing movements and sustained, painful, muscle contractions).

In the standard MPTP monkey model, treatment with ADX48621 resulted in a significant...

Read the full 570 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >